饮食诱导NAFLD小鼠模型整合研究揭示PPARα为性别二态性药物靶点
该研究比较了高脂饮食、胆碱缺乏高脂饮食、西方饮食或补充果糖葡萄糖的西方饮食与对照饮食在雄性和雌性小鼠中诱导的非酒精性脂肪性肝病(NAFLD)表型,发现雄性小鼠对NAFLD易感性增加,肝脏PPARα共表达网络存在性别二态性,且肝细胞PPARα决定对禁食和pemafibrate的性别特异性反应,人类肝脏分子特征也支持PPARα的性别特异性共表达网络。
要点
- 雄性小鼠对饮食诱导的NAFLD更易感,高脂饮食下脂质蓄积最严重,西方饮食下炎症/纤维化最严重。
- 肝脏PPARα共表达网络呈现性别二态性,肝细胞PPARα决定禁食和pemafibrate治疗的性别特异性反应。
- 人类肝脏分子特征也显示性别二态性基因表达谱和PPARα的性别特异性共表达网络。
核心结论
- 饮食诱导NAFLD小鼠模型存在性别特异性表型,雄性更易感,PPARα是关键的性别二态性药理靶点。
研究设计与样本
- 研究比较了高脂饮食、胆碱缺乏高脂饮食、西方饮食或补充果糖和葡萄糖饮用水的西方饮食与对照饮食在雄性和雌性小鼠中的NAFLD模型,进行了代谢表型分析、肝脏代谢组/脂质组/转录组无靶向大规模分析、基因表达谱和网络分析,并有人类肝脏分子特征分析,试验注册号NCT02390232。
主要发现
- 不同饮食诱导性别特异性反应,雄性小鼠对NAFLD易感性增加;最严重的脂质蓄积出现在接受高脂饮食的雄性,最严重的炎症/纤维化出现在接受西方饮食的雄性。
- 不同饮食挑战下鉴定出性别偏倚的肝脏基因特征;PPARα共表达网络被鉴定为性别二态性。
- 小鼠体内实验证明肝细胞PPARα决定对禁食和pemafibrate(选择性PPARα激动剂)治疗的性别特异性反应。
- 人类肝脏分子特征也提供性别二态性基因表达谱和PPARα性别特异性共表达网络的证据。
临床怎么用
- 在NAFLD基础和临床研究中应充分考虑性别差异,PPARα作为药物靶点需关注性别特异性反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluated the influence of sex on the pathophysiology of non-alcoholic fatty liver disease (NAFLD). We investigated diet-induced phenotypic responses to define sex-specific regulation between healthy liver and NAFLD to identify influential pathways in different preclinical murine models and their relevance in humans. DESIGN: Different models of diet-induced NAFLD (high-fat diet, choline-deficient high-fat diet, Western diet or Western diet supplemented with fructose and glucose in drinking water) were compared with a control diet in male and female mice. We performed metabolic phenotyping, including plasma biochemistry and liver histology, untargeted large-scale approaches (liver metabolome, lipidome and transcriptome), gene expression profiling and network analysis to identify sex-specific pathways in the mouse liver. RESULTS: The different diets induced sex-specific responses that illustrated an increased susceptibility to NAFLD in male mice. The most severe lipid accumulation and inflammation/fibrosis occurred in males receiving the high-fat diet and Western diet, respectively. Sex-biased hepatic gene signatures were identified for these different dietary challenges. The peroxisome proliferator-activated receptor α (PPARα) co-expression network was identified as sexually dimorphic, and in vivo experiments in mice demonstrated that hepatocyte PPARα determines a sex-specific response to fasting and treatment with pemafibrate, a selective PPARα agonist. Liver molecular signatures in humans also provided evidence of sexually dimorphic gene expression profiles and the sex-specific co-expression network for PPARα. CONCLUSIONS: These findings underscore the sex specificity of NAFLD pathophysiology in preclinical studies and identify PPARα as a pivotal, sexually dimorphic, pharmacological target. TRIAL REGISTRATION NUMBER: NCT02390232.
引用
- Smati S, Polizzi A, Fougerat A, et al. Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target. Gut. 2021. PMID: 33903148. doi:10.1136/gutjnl-2020-323323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。